DONATE

Bladder cancer

Three IBEC researchers receive grants from the Spanish Association Against Cancer

Three research projects led by IBEC researchers Xavier Rovira-Clavé, David Esporrín Ubieto and Aránzazu Villasante have been selected by the Spanish Association Against Cancer for its 2025 Grant Programme. The grant presentation ceremony, held in Barcelona today, recognised the momentum behind these initiatives, which range from advanced cell therapy platforms to smart nanomotors and innovative paediatric tumour treatment strategies.

IBEC research takes third place in the 2025 Vanguardia de la Ciencia Awards

A study led by IBEC has won the 3rd Vanguardia de la Ciencia 2025 Prize. The research, led by Samuel Sánchez Ordoñez and with Meritxell Serra-Casablanca as lead author, proposes an innovative bladder cancer therapy based on nanorobots loaded with radiopharmaceuticals. These nanorobots are capable of moving around the bladder using urine as a source of energy.

Novel nanomotors improve bladder cancer immunotherapy

A study led by the Institute for Bioengineering of Catalonia (IBEC) and Pohang University of Science and Technology (POSTECH) in South Korea describes the development of urea-powered nanomotors that improve immunotherapy for bladder cancer. The nanomotors activate the immune system more efficiently and exceed the efficacy of currently used treatments, opening up new possibilities in oncology.

Nanomedicine experts gather on World Cancer Nanoday

Once again, experts in nanomedicine from various fields gathered in Barcelona on the occasion of World Cancer Day. The meeting provided an opportunity to showcase the latest innovations in nanomedicine for combating cancer, covering topics such as early diagnosis, controlled drug release, and radiotherapy employing nanoparticles.

Bladder tumours reduced by 90% using nanorobots

The research, which was conducted on mice, demonstrates how these tiny nanomachines are propelled by urea present in urine and precisely target the tumour, attacking it with a radioisotope carried on their surface. Led by the IBEC and CIC biomaGUNE, the study opens the door to new, more efficient treatments for bladder cancer.